Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Abstract

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).

Keywords

AlogliptinAcute coronary syndromeType 2 diabetesMedicineInternal medicineDiabetes mellitusCardiologyMyocardial infarctionEndocrinologyDipeptidyl peptidase-4

Affiliated Institutions

Related Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic , Meg Jardine , Bruce Neal +21 more

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a med...

2019 New England Journal of Medicine 5513 citations

Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis

Enrico Ammirati , Manlio Cipriani , Claudio Moro +35 more

Background: There is controversy about the outcome of patients with acute myocarditis (AM), and data are lacking on how patients admitted with suspected AM are managed. We repor...

2018 Circulation 396 citations

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

R B Sleight , Peter Sleight , Sarah Parish +3 more

17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (...

1988 PubMed 2873 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

Publication Info

Year: 2013
Type: article
Volume: 369
Issue: 14
Pages: 1327-1335
Citations: 2475
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2475

OpenAlex

Cite This

APA Style

                            
                                
                                    William B. White, 
                                
                                    Christopher P. Cannon, 
                                
                                    Simon Heller
                                
                                et al.
                            
                            (2013). 
                            Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 369
                            (14)
                            , 1327-1335.
                            https://doi.org/10.1056/nejmoa1305889
                        

Identifiers

DOI: 10.1056/nejmoa1305889